Maximierung der Sicherheit von Flibanserin: Die Rolle von Aufsichtsbehörden, Klinikern und Patientinnen^[1]

^a Center for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore/USA

^b Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore/USA

^c Division of General Internal Medicine and Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh/USA

^d Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh/USA

^a Center for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore/USA

^b Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore/USA

^e Department of Medicine, Johns Hopkins Medicine, Baltimore/USA